Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

NCT06079359 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypophosphatasia

Interventions

DRUG: ALXN1850
DRUG: Placebo

Sponsor

Alexion Pharmaceuticals, Inc.